House Democrat Calls Congress ‘The Poster Child for Cowardice” on ISIS
Amid growing signs that the U.S. faces nothing but bad choices in its war against ISIS, Rep. Jim McGovern, a liberal Democrat from Massachusetts, today denounced Congress as “the poster child for cowardice” for refusing to debate a new war powers resolution to set parameters for the Obama administration’s efforts to “degrade and defeat” the jihadist terrorists in Iraq and Syria.
At the behest of Republican and Democratic leaders, Obama sent a proposed war powers resolution to Congress in February outlining his core objectives of systematically destroying the jihadist terror group through a sustained campaign of airstrikes, supporting and training allied forces on the ground and humanitarian assistance – but without committing a large number of U.S. combat troops to the effort.
Related: U.S. Shoots Itself in the Foot By Accidentally Arming ISIS
The administration proposal would give the military “flexibility” to confront unforeseen circumstances, potentially by deploying Special Forces in the region. But it would limit the mission to three years and would not authorize “enduring offensive ground combat operations.”
But rather than roll up their sleeves and debate and vote on the president’s request for new military authorization, Republican leaders have effectively shelved the issue and moved on to other things, such as rewriting the rules for NSA spying on Americans’ phone calls and providing Obama with fast track authority to negotiate a new trade pact with Asian countries.
With many conservative Republicans including Sens. John McCain of Arizona and Lindsey Graham of South Carolina complaining that the president’s strategy for defeating ISIS woefully inadequate and some Democrats worried that it goes too far in committing U.S. troops and resources to a no-win situation in the Middle East, Senate Foreign Relations Committee Chair Bob Corker (R-TN) said recently he had no incentive to take up the issue in his committee.
Related: Why Congress Should Simply Bag the War Powers Debate
Frankly speaking, this is unacceptable,” McGovern, a member of the House Rules Committee, said on the House floor today, adding that if the Congress “doesn’t have the stomach” to authorize the war it should vote to bring U.S. forces home, according to Politico. McGovern introduced a bipartisan resolution that would require full debate within 15 days on whether U.S. troops should withdraw from Iraq and Syria. His bipartisan resolution is co-sponsored by Reps. Walter Jones (R-NC) and Barbara Lee (D-CA).
“This House appears to have no problem sending our uniformed men and women into harm’s way,” McGovern said in prepared remarks. “It appears to have no problem spending billions of dollars for the arms, equipment and airpower to carry out these wars. But it just can’t bring itself to step up to the plate and take responsibility for these wars.”
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.